Introduction
Gastric cancer is the most frequent malignancy in Japan and the second leading cause of death in the world [1] . Although the mortality has gradually decreased with an increasing incidence in the detection of early-stage disease in Japan, more than 50% of advanced cases recur, even after a curative resection [2] . The prognosis is extremely poor in patients with recurrent or unresectable gastric cancer [3] . Reliable and convenient bio-cance of TIMP-1 levels in regard to long-term survival has not been clarifi ed. In the present study, we followed the same cohort of 149 patients for more than 5 years prospectively. The long-term survival results were analyzed to clarify the prognostic value of plasma TIMP-1 levels in patients with gastric cancer.
Patients and methods

Patients
Plasma samples were obtained preoperatively from 149 patients with primary gastric adenocarcinoma. None of the patients had undergone any prior treatment. Subsequently, these patients underwent either a total or subtotal gastrectomy at the Kanagawa Cancer Center (Yokohama, Japan) between August 1996 and February 1998. The extent of the tumor was evaluated by the International Union Against Cancer (UICC)/ TNM staging system [22] . Metastases to the liver, lymph nodes, and peritoneum were diagnosed by computed tomography (CT) and then were confi rmed during surgery. Metastases to the lung were diagnosed by CT or chest X-ray. Patients who had suspected symptoms of distant metastases were further examined. The patients were followed after surgery for more than 5 years prospectively. The outcomes were evaluated during clinical appointments at the outpatient clinic or by telephone contact.
Measurement of plasma TIMP-1 concentration
A one-step sandwich enzyme-linked immunosorbent assay (ELISA) kit (Fuji Chemical, Takaoka, Japan) was used to measure the plasma concentration of TIMP-1 [23] . The cutoff value of plasma TIMP-1 was set at 112.5 ng/ml based on our previous report [20] .
Statistical analyses
A χ 2 test was used to compare results the between low and high plasma TIMP-1 groups [24] . The survival curves were calculated using the Kaplan-Meier method and compared using the log-rank test. Cox's proportional hazard model was used to perform univariate and multivariate survival analyses. A P value of less than 0.05 was defi ned as statistically signifi cant, and the values for data were expressed as means ± SDs. We used SPSS software (v11.0J Win; SPSS; Chicago, IL, USA) to conduct all statistical tests.
Results
Clinicopathological factors
Plasma TIMP-1 was positive in 30 of the 149 patients (20.1%). When the clinicopathological factors observed in the patients with positive and those with negative plasma TIMP-1 were compared, signifi cant differences were observed in the depth of tumor invasion (T), nodal metastases (N), distant metastases (M), R category (R), and the stage of the disease (Table 1) .
Survival analyses
The median follow up period was 63.9 months. The Kaplan-Meier survival curves were signifi cantly different between patients with negative and those with positive plasma TIMP-1 (Fig. 1) . The overall survival rate was 78.2% at 5 years in patients with negative plasma TIMP-1, while the rate was 26.7% at 5 years in patients with positive plasma TIMP-1. A univariate analysis for overall survival revealed the depth of T, N, M, and the R category, and plasma TIMP-1, to be statistically signifi cant prognostic factors ( Table 2) . A multivariate Cox proportional hazards analysis demonstrated that T, N, and plasma TIMP-1 were independent prognostic factors, but M and R0 were not (Table 3) .
When the survival analyses were limited to M0 and R0, the Kaplan-Meier survival curves were signifi cantly different between patients with negative and those with positive plasma TIMP-1 (Fig. 2) . The overall survival rate was 84.6% at 5 years in patients with negative plasma TIMP-1, while the rate was 53.3% at 5 years in patients with positive plasma TIMP-1. A multivariate analysis demonstrated that T and plasma TIMP-1 were signifi cant and independent prognosticators, but N was not (Table 4) . (Table 5) The initial recurrence site was examined in 127 patients who underwent R0 resection. Any recurrence was observed in 18 of 112 patients with negative TIMP-1 and in 6 of 15 patients with positive TIMP-1. The most frequent initial site was peritoneum in both groups. Recurrence patterns were not different between these two groups (P = 0.377).
Recurrence patterns
Discussion
Our previous report showed a positive correlation between elevated plasma TIMP-1 and tumor invasiveness and metastasis in 149 patients with gastric cancer [19] . Moreover, our next report demonstrated the plasma TIMP-1 concentration to be an independent prognosticator for the short-term survival of patients with gastric carcinoma [20] . In that study, however, the observation period ranged from 350 days to 650 days, which was too short to reach conclusions on the prognostic value. Moreover, 2 patients were excluded from the initial 149 patients due to the very short period of The log-rank test revealed a statistically signifi cant difference between the two groups the follow up, and the remaining 147 patients were analyzed. In addition, the disease stage had been evaluated by the Japanese classifi cation of gastric carcinoma (JCGC) of the Japanese Research Society for Gastric Cancer [25] , which defi nes nodal metastasis by the location of metastatic nodes. In the present study, all of the patients were followed for more than 5 years and tumor spread was evaluated using the UICC/TNM, which refl ects survival more accurately than the JCGC [26] . The JCGC, UICC/TNM defi nes nodal metastasis by the number of metastatic nodes. Plasma TIMP-1 concentrations were found to be correlated with serosal invasion, metastases, and advanced stages of the disease [19] . This suggests the plasma TIMP-1 concentration to be a prognosticator for long-term survival. In the present study, the cutoff value for TIMP-1 was the same as that used in our previous study [19] , in which the cutoff value had been determined by the TIMP-1 value in mucosal cancer. Mucosal cancer or noninvasive carcinoma does not initiate the degradation processes in which matrix metalloproteinases may play important roles. With this cutoff value, the concentration of plasma TIMP-1 was a signifi cant factor for long-term survival, based on both univariate and multivariate analyses, suggesting that the concentration of plasma TIMP-1 is as strong an independent prognosticator as T, N, and the R category. However, the validity of the plasma TIMP-1 concentration using this cutoff value should be confi rmed in an independent cohort of patients in a future study. Generally, the most important factors affecting survival were T, N, M, and the R category. In the present study, multivariate analysis revealed that T, N, and plasma TIMP-1 expression were statistically signifi cant indicators for survival; the M factor and R category were not independent factors in this study. When the survival analyses were limited to M0 and R0, T and plasma TIMP-1 were still independent prognostic factors, based on a multivariate analysis. Considering the value of the prognosticators, plasma TIMP-1 expression was found to be superior to N in terms of the P value and hazard ratio and plasma TIMP-1 expression was superior to T in terms of the hazard ratio in this analysis. These results indicate that plasma TIMP-1 concentration is a promising and powerful independent prognostic factor in patients with gastric cancer, in comparison to the conventional factors such as T, N, M, and the R category.
The prognostic signifi cance of TIMP-1 levels in the circulating blood has been examined in several types of malignancy [10] [11] [12] [13] [14] [15] [16] . The prognostic value of TIMP-1 was confi rmed in cancer of the ovary by Manenti et al. [10] , in cancer of the lung by Ylisirnio et al. [16] , and in cancer of the breast by Kuvaja et al. [18] , while the results were controversial for colorectal cancer [11] [12] [13] [14] [15] . Holten-Andersen et al. [11, 15] and Yukawa et al. [14] showed the prognostic signifi cance of plasma concentrations of TIMP-1 in patients with colorectal cancer. Ishida et al. [13] and Oberg et al. [12] measured serum samples and demonstrated no signifi cant correlation between TIMP-1 levels and survival. In another report, Holten-Anderson et al. [27] examined serum and plasma samples for the measurement of TIMP-1 and concluded that serum was not suitable because the serum TIMP-1 was affected by repeated freezing and thawing. Plasma samples may be required to evaluate the clinical signifi cance of TIMP-1 accurately.
Previously, we measured TIMP-1 proteins in gastric cancer tissues quantitatively and found that intratumoral TIMP-1 protein was elevated in more aggressive tumors and was a signifi cant factor for survival [28] . Murray et al. [6] examined TIMP-1 expression in gastric cancer by immunohistochemistry. They found that TIMP-1 expression was confi ned to tumor cells [6] . On the other hand, Joo et al. [8] reported that TIMP-1 expression was detected predominantly in the peritumoral stromal cells rather than tumor cells. Thus, TIMP-1 protein is produced both in tumor and stromal cells and then fl ows into the bloodstream.
In the present study, prognostic signifi cance was observed not only in the analysis of all patients but also in the analysis of M0 and R0. Moreover, the plasma TIMP-1 expression clearly separated patients with a good and a poor prognosis, regardless of the nodal status and the stage, thus suggesting that plasma TIMP-1 could be a prognosticator not only for early disease but also for advanced disease. In other words, even patients classifi ed as in the same stage include subgroups with a different risk for survival, which was clearly separated by the plasma TIMP-1 concentration. HoltenAnderson et al. [11] also showed that survival was associated with the concentration of plasma TIMP-1 in Dukes' stage B in patients with colorectal cancer. Therefore, the plasma TIMP-1 concentration may be used to separate patients with good and poor prognoses.
Among the prognostic factors, the plasma level of TIMP-1 has a great advantage in comparison to other prognosticators such as T, N, and M because it requires a far less invasive procedure to yield useful information. T and N are predicted by clinical examinations such as Some patients had initial recurrence in more than one site endoscopy, endoscopic ultrasonography, and CT, and must be confi rmed by the pathological examination of resected specimens. M is evaluated by CT, laparoscopy, and laparotomy. On the other hand, only a blood sample is required for the measurement of plasma TIMP-1 concentrations. Moreover, the ELISA technique is convenient, reproducible, and reliable. Therefore, plasma TIMP-1 concentration could provide useful prognostic information by a simple and less invasive method in patients with gastric cancer. Recurrence patterns were not different when stratifi ed by TIMP-1 positivity. This suggests that TIMP-1 may not be a marker for specifi c recurrence patterns, although the number of recurrences was too small to reach a defi nite conclusion.
In conclusion, the results of the present study suggested that plasma TIMP-1 expression was a signifi cant strong independent prognosticator for the survival of patients with gastric cancer.
